What Nurix Therapeutics does

Nurix Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Brisbane, California (NASDAQ: NRIX). The company develops small-molecule drugs based on targeted protein degradation (TPD), an approach that uses the cell's own ubiquitin-proteasome system to eliminate disease-causing proteins rather than merely inhibiting them, and applies this approach to hematologic cancers, solid tumors, and autoimmune and inflammatory diseases. Its discovery engine, called DEL-AI, combines DNA-encoded library (DEL) screening of more than 5 billion chemical structures with automated chemistry and machine learning, and is supported by expertise in E3 ligase biology that has reportedly enabled over 90 distinct E3 ligases for drug discovery versus the two (cereblon and VHL) historically used in the field.

The pipeline is anchored by the oral BTK degrader bexobrutideg (NX-5948), which reported an 83% objective response rate in heavily pretreated relapsed/refractory CLL patients and entered a pivotal Phase 2 trial in late 2025, alongside a second BTK degrader (zelebrudomide/NX-2127) in Phase 1, the oral CBL-B inhibitor NX-1607 in Phase 1 for solid tumors, the partnered IRAK4 degrader GS-6791/NX-0479 with IND clearance in April 2025, the partnered STAT6 degrader NX-3911 with Sanofi, and earlier-stage oncology assets and a degrader-antibody conjugate (DAC) modality.

Nurix operates a partnership-driven business model: it generates revenue almost entirely from upfront payments, research funding, and milestone payments under collaborations with Roche (bexobrutideg, $700M upfront and up to $2.3B total), Gilead Sciences (IRAK4 program), Sanofi (STAT6 program), and Pfizer/Seagen (DACs), and finances clinical development through periodic public equity offerings (notably $250M in October 2025 and $175M in April 2024). The company plans to co-commercialize bexobrutideg directly in the United States while relying on partner infrastructure for ex-US markets, and reported $83.7M in annual operating revenue alongside a substantial operating loss and a Q1 2026 cash position of approximately $540.7M before the Roche payment.

Name

Nurix Therapeutics

Legal name

Nurix Therapeutics, Inc.

Website

https://nurixtx.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for hematologic cancers, solid tumors, and autoimmune diseases using its proprietary DEL-AI platform that combines DNA-encoded libraries, machine learning, and E3 ligase biology.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Targeted protein degradation
• Biopharmaceutical drug discovery
• BTK degrader therapeutics
• E3 ligase modulators
• Degrader-antibody conjugates

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership/Collaboration Revenue: Nurix derives revenue primarily from strategic partnerships with pharmaceutical companies including Roche, Gilead, Sanofi, and Pfizer/Seagen. These partnerships provide upfront payments, milestone payments (development, regulatory, and commercial), and potential royalties on product sales. The company has secured over $3 billion in potential milestone value across partnerships.
2. Equity Financing: Pre-revenue clinical-stage company financed through public equity offerings. Completed $250M registered offering in October 2025, $175M in April 2024, and $40M in July 2022.
3. Research Funding: Revenue from collaborative research arrangements with pharmaceutical partners funding specific research programs.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Nurix Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule targeted protein degradation (degrader) medicines for hematologic cancers, solid tumors, and autoimmune/inflammatory diseases. Its core asset is the proprietary DEL-AI Discovery Engine that combines DNA-encoded libraries with machine learning to design novel degrader compounds, which feed a multi-asset pipeline (bexobrutideg, zelebrudomide, NX-1607, GS-6791, NX-3911, NRX-0305, NRX-4972, plus a DAC modality). The company monetizes these assets primarily through global partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen that generate upfront payments, R&D funding, milestones, and royalties.

Product overview

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for cancer and autoimmune diseases. The company's platform, DEL-AI, combines DNA-encoded libraries with machine learning for drug discovery. The pipeline includes multiple degrader candidates: Bexobrutideg (BTK degrader, Phase 2 for CLL) and Zelebrudomide/NX-2127 (BTK degrader, Phase 1) for B-cell malignancies; NX-1607 (CBL-B inhibitor, Phase 1) for solid tumors; GS-6791 (IRAK4 degrader) for inflammation; and NRX-0305/NRX-4972 preclinical oncology programs. The company also develops Degrader-Antibody Conjugates (DACs). Strategic partnerships with Roche (up to $2.3B for bexobrutideg), Gilead (IRAK4 degrader), Sanofi (STAT6 degrader), and Pfizer/Seagen (DACs) validate the platform.

Differentiator

Problem solved

Functional benefit

Products and services

• DEL-AI Discovery Engine Proprietary AI-powered drug discovery platform that integrates DNA-encoded library (DEL) screening data, automated chemistry, and machine learning to identify and optimize novel targeted protein degrader compounds; features more than 5 billion unique chemical structures and has enabled more than 90 distinct E3 ligases for drug discovery. The platform underpins all of Nurix's internal pipeline and is the foundation of its partnerships with Roche, Gilead, Sanofi, and Pfizer/Seagen.
• Bexobrutideg (NX-5948) Oral, blood-brain barrier-penetrating BTK degrader in pivotal Phase 2 (DAYBreak) development for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with Phase 1 expansion into Waldenström macroglobulinemia, DLBCL, MCL, MZL, FL, PCNSL, and autoimmune indications including chronic spontaneous urticaria. Demonstrated an 83% objective response rate in 47 evaluable CLL patients (median 3 prior therapies) and 75% ORR in Waldenström macroglobulinemia. Subject of a global co-development and co-commercialization agreement with Roche worth up to $2.3 billion announced in June 2026.
• Zelebrudomide (NX-2127) Oral BTK degrader in Phase 1 clinical development for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and other hematologic cancers. Earlier-stage BTK degrader program that complements bexobrutideg within Nurix's B-cell malignancy strategy.
• NX-1607 Oral CBL-B inhibitor in Phase 1 clinical development for patients with advanced malignancies, including ovarian, gastric, head and neck, melanoma, non-small cell lung cancer, prostate, breast, and urothelial cancers. Phase 1 data demonstrated immune activation and tumor microenvironment remodeling, supporting its role in immuno-oncology combination strategies.
• GS-6791 / NX-0479 (IRAK4 Degrader) IRAK4 degrader for inflammatory diseases that received FDA IND clearance in April 2025 and is now in Phase 1 clinical trials. Developed under the global strategic collaboration with Gilead Sciences (originally signed 2019, expanded in 2024), with Gilead having exercised its option to exclusively license the program in 2023.
• NX-3911 (STAT6 Degrader) STAT6 degrader for inflammatory diseases, advancing through IND-enabling studies under the global strategic collaboration with Sanofi. Sanofi exercised its license extension option to the program in 2025 and has assumed the cost of IND-enabling studies. The program targets Th2-mediated inflammatory diseases where disruption of IL-4/IL-13 signaling via STAT6 degradation may provide differentiated efficacy.
• NRX-0305 (Pan-mutant BRAF Degrader) Pan-mutant BRAF degrader for melanoma (including brain metastases) and other BRAF-driven cancers. Preclinical data presented at AACR 2026 demonstrated a 142% lifespan increase versus 12% for dabrafenib in a melanoma brain metastasis model, supporting its potential as a differentiated therapy for BRAF-mutant tumors, including those that have metastasized to the brain.
• NRX-4972 (Aurora Kinase A Degrader) Aurora Kinase A degrader for oncology applications. Preclinical data were presented at the AACR 2026 annual meeting, supporting its development for tumors dependent on Aurora Kinase A activity, where targeted degradation may offer improved selectivity and durability over traditional kinase inhibitors.
• Degrader-Antibody Conjugates (DACs) Innovative therapeutic modality that combines the cell-targeting specificity of monoclonal antibodies with the potency, selectivity, and catalytic activity of targeted protein degraders, with the goal of producing cancer medicines with enhanced precision and improved safety. Developed as a new therapeutic class under the Seagen/Pfizer collaboration announced in 2023.

Quantifiable outcome

• 83% objective response rate in relapsed/refractory CLL patients with bexobrutideg (47 evaluable patients, median 3 prior therapies)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• RochecoreStrategic or Co-development Partner · 8 June 2026Global collaboration to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell malignancies, immunology, and neurology indications. Roche pays $700M upfront with potential total deal value up to $2.3B. Development costs split 60/40 (Roche/Nurix). US profits shared equally; Roche handles ex-US commercialization with royalties to Nurix.
• Pfizer (formerly Seagen)minorStrategic or Co-development Partner · 1 January 2023Strategic collaboration with Seagen (now part of Pfizer) to advance degrader antibody conjugates (DACs) as an innovative new class of cancer therapeutics combining antibody specificity with degrader potency.
• SanoficoreStrategic or Co-development Partner · 1 January 2020Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Expanded in 2021. Sanofi exercises license extension option to STAT6 program (2025). STAT6 degrader NX-3911 in IND-enabling studies with Sanofi assuming IND-enabling costs.
• Gilead SciencescoreStrategic or Co-development Partner · 1 January 2019Global strategic collaboration to discover, develop, and commercialize targeted protein degradation drugs. Gilead exercised option to exclusively license Nurix's IRAK4 degrader (2023). Collaboration extended in 2024. IRAK4 degrader GS-6791/NX-0479 in Phase 1 clinical trials.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation using PROTAC technology for cancer and other diseases. Direct competitor to Nurix in the protein degrader space with overlapping BTK and other oncology programs. Arvinas has multiple clinical-stage assets and established pharma partnerships, making it the most directly comparable peer.
• Kymera Therapeutics: Clinical-stage biopharmaceutical company developing targeted protein degraders with a proprietary Pegasus platform. Direct competitor in BTK and immunology degrader space; both companies compete for the same target classes and partnership economics with major pharma.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and other diseases. Direct peer in the targeted protein degradation space with a different but overlapping modality (glue degraders vs. PROTACs) addressing similar oncology and immunology indications.
• C4 Therapeutics: Clinical-stage company developing small-molecule degraders using its TORPEDO platform for cancer and neurodegenerative diseases. Direct peer competing in the degrader space with multiple clinical-stage assets and pharma partnerships.
• Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory biology, including protein degradation approaches for cancer. Direct competitor with overlapping oncology focus and similar clinical-stage profile as Nurix.

Emerging players

• Neomorph: Privately held biotech co-founded by protein degradation pioneer Ray Deshaies focused on next-generation molecular glue degraders. Emerging player in the same degrader space, comparable through shared focus on E3 ligase-enabled targeted protein degradation.
• Lycia Therapeutics: Emerging biotech developing LYTACs (lysosome-targeting chimeras), an alternative degradation modality. Comparable to Nurix through shared focus on expanding the druggable protein universe via novel degradation approaches.
• BioTheryX (acquired by Incyte): Protein degradation-focused biotech (now part of Incyte) with a molecular glue approach to challenging oncology targets. Comparable through shared focus on E3 ligase-based protein degraders for hematology and oncology.

Broad incumbents

• Pfizer: Major pharmaceutical company that is both a Nurix partner (via Seagen acquisition, for DACs) and a broad incumbent in hematology/oncology with internal degrader-adjacent programs and competing BTK inhibitors. Comparable through overlap in target indications and partnership dynamics.
• Amgen: Large biopharmaceutical incumbent with established presence in hematology/oncology and biologics manufacturing. Comparable through overlapping therapeutic focus on B-cell malignancies and inflammation, plus broader infrastructure that competes with Nurix's partnered programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nurixtx
• Xx.com/Nurix_Tx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nurix Therapeutics